Skip to Content
MilliporeSigma

Skip To

SML2074

FX1

≥98% (HPLC)

Synonym(s):

(5Z)-5-(5-Chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)-4-oxo-2-thioxo-3-thiazolidinepropanoic acid, (Z)-3-(5-(5-Chloro-2-oxoindolin-3-ylidene)-4-oxo-2-thioxothiazolidin-3-yl)propanoic acid

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Size/SKUAvailabilityPrice
25 mg

Available to ship TODAYfromMILWAUKEE

$467.00
$396.95

About This Item

Empirical Formula (Hill Notation):
C14H9ClN2O4S2
CAS Number:
Molecular Weight:
368.82
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder

$396.95

List Price$467.00Save 15%
Web-Only Promotion

Available to ship TODAYDetails


Request a Custom Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


assay

≥98% (HPLC)

form

powder

color

red-brown

storage temp.

2-8°C

SMILES string

S1\C(=C2\c3c(ccc(c3)Cl)NC\2=O)\C(=O)N(C1=S)CCC(=O)O

InChI key

VISHSGZPGQKEFX-KHPPLWFESA-N

Biochem/physiol Actions

FX1 is a BCL6 inhibitor that effectively blocks BCL6 N-terminal BTB domain-mediated corepressors chromosome recruitment (by 61-87%/SMRT and 67-82%/BCOR; 50 μM FX1 for 30 min) and selectively suppresses BCL6-depenent growth (GI50 16-54 μM; >125 μM against BCL6-independent cells) in diffuse large B cell lymphoma (DLBCL) cultures, exhibiting greater affinity than its structure analog 79-6 or BCL6 corepressor SMRT for BTB domain (KD = 7 μM/FX1, 30 μM/SMRT, 129 μM/79-6). FX1 shows greater efficacy than 79-6 in reversing BCL6/corepressors-mediated target genes repression in vitro (IC50 = 35 μM vs. 318 μM with 79-6 by HEK293T-based reporter assay) and in suppressing OCI-Ly7 DLBCL xenograft tumor growth mice in vivo (100% vs. 45% suppression with respective compound via 25 mg/kg/day i.p.).
Second generation 79-6 derived BCL6 inhibitor with improved efficacy against diffuse large B cell lymphoma (DLBCL) both in vitro and in vivo.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
X3629SML1735SML2688
description

≥98% (HPLC)

description

≥98% (HPLC)

description

≥98% (HPLC)

description

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

form

powder

form

powder

form

powder

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

color

red-brown

color

orange

color

white to beige

color

white to beige


Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Questions

  1. What is the procedure for solubilizing or preparing product SML2074 for use or injection?

    1 answer
    1. We don't have an in-house protocol for the use of BCL6 Inhibitor, FX1 in vivo. However, there are relevant citations in the published literature. For example:

      - "Mice were assigned in a randomized way to treatment groups and treated i.p. with 25 or 50 mg/kg/d of the drugs. Drugs were reconstituted in PEG-400 and stored at –20°C until use."
      - "Mice were exposed to either vehicle (DMSO) or FX1 1 h prior to the LPS (10 mg/kg) challenge."
      - "Mice were injected i.p. with 50 mg/kg of compound in vehicle (35% PEG-300, 5% Tween-80, 65% Dextrose 5%, n=8) or vehicle alone (n=2)."

      Additional citations can be found by conducting a search for "inject BCL6 inhibitor FX1 mg/kg DMSO."

      Helpful?

Reviews

No rating value

Active Filters